Potency Management for Pharmaceuticals in Sage X3 Sage X3 Tips, Tricks and Components

With a background that includes both science and finance, Kimi has carefully crafted a financial strategy that has allowed Sage to remain a nimble, independent, and innovative biopharmaceutical company. She joined Sage as CFO in 2013, bringing financial and operating strength sage x3 pharmaceuticals from her senior management experiences at established, and emerging, life science companies. Prior to joining Sage, Kimi served as Chief Operating Officer, North America, for Santhera Pharmaceuticals, and Vice President of Finance at Cyberkinetics Neurotechnology Systems.

Ms. Barrett was previously Global President of Oncology at Pfizer, Inc. While at Pfizer, Ms. Barrett held numerous leadership positions, including President of Global Innovative Pharma for Europe, President of the Specialty Care business unit for North America, and President of United States Oncology. Prior to Pfizer, she was Vice President and General Manager, Oncology business unit at Cephalon Inc. from 2006 to 2009, where she built the unit from scratch and launched Cephalon into Oncology. Ms. Barrett also worked at Johnson & Johnson across their consumer, diagnostics and biopharma sectors. Careers.sagerx.comand entering a website that is not owned or controlled by Sage Therapeutics, Inc.

This minimize wastes with controlled production with reduced inventory costs. It involves different stakeholders such as the manufacturers, national regulators, government ministries, wholesalers and others. Developing the industry requires concerted support from business management solution like Sage X3 so that industry can flourish and realize its full potential. At Greytrix Africa we understand the complexities of the industry and provide you with holistic solution that help you abide the stringent rules with the region’s health sectors, involve legislations and stay ahead of competition. During his tenure at Celgene, George developed new models for corporate collaborations, and led a business development effort that saw Celgene become “Partner of Choice” according to Boston Consulting Group Survey data.

  • Vanessa began her career working as a staff member in the United States Congress, where she served as a senior health policy advisor.
  • Prior to joining Myriad in 2020, Mark was Chairman of the Department of Psychiatry and Behavioral Sciences at Rush University Medical Center and Director of its Mental Health Service Line.
  • Sage Therapeutics, Inc. makes no representation as to the accuracy of the information contained on websites it does not own or control.
  • Vanessa aligns the activities of Sage’s communications, public policy, government affairs, and patient advocacy teams, to advance Sage’s patient-centric mission.
  • Prior to joining Choate, she was Senior Vice President, Business & Corporate Development, General Counsel at ViaCell, Inc., and Chief Corporate Counsel at Biogen.

Previously, he spent eight years at UCB in commercial roles of increasing responsibility including Global Launch Head, Commercial and Medical Affairs, Immunology and Global Commercial Strategy Lead, Immunology. He began his career in sales at Johnson & Johnson and held sales leadership and senior marketing roles at Takeda. Kevin is a proven operational leader with more than 25 years of experience building and operating leading biotech companies. Kevin co-founded Third Rock Ventures in 2007 and focuses on the formation, development and business strategy of the firm’s portfolio companies as well as actively identifying and evaluating new investments. Earlier in his career, he served in various executive roles at Millennium BioTherapeutics, Biogen and Digital Equipment Corporation. Anne Marie thoughtfully guides Sage on legal strategy, intellectual property, corporate governance, and more.

Software and services for every business

Mike is a trained neurophysiologist and translational scientist with over 25 peer reviewed manuscripts in areas of neurotransmission, memory formation and retrieval, and neural mechanisms of decision-making and goal-directed behavior. He holds both a S.B degree in Cognitive Science and a Ph.D. in Systems Neuroscience from the Massachusetts Institute of Technology and completed his post-doctoral training the Cold Spring Harbor Laboratory in New York. And a Ph.D. in Neuroscience from Case Western Reserve University and a B.S. She completed an internship in Pediatrics, followed by residency in Adult Psychiatry and fellowship in Child and Adolescent Psychiatry at Yale University. As Chief Medical Officer for Sage, Dr. Gault focuses on advancing the development and delivery of Sage’s current and emerging product pipeline. For more information on Sage Enterprise Management Consulting Services, please contact us at will be glad to assist you.

sage x3 pharmaceuticals

Michael has served as president of specialty pharmaceuticals at Shire Plc, a global specialty pharmaceutical company he first joined in 2005 as executive vice-president of global therapeutic business units and portfolio management. Previously, Michael also served as a growth capital provider and president of the life sciences group for Safeguard Scientifics, Inc., where he served as chairman and chief executive officer of Clarient, Inc., and chairman of Laureate Pharma, Inc. In addition, Michael has held senior positions in product development and commercialization at AstraMerck and AstraZeneca. Mr. Germano has over 30 years of experience in the pharmaceutical industry and a consistent track record of improving operating performance and increasing shareholder value.

Sage People

Ensure food quality and safety with end-to-end traceability and quality control. Control your bottom line ably with real-time global visibility and local compliancy. Advanced financial management platform for professionals with a growing business. Sage Business Cloud Accounting and Payroll, formerly Sage One, is also a part of the wider Sage Business Cloud brand but aimed at smaller enterprises. The product line which evolved into Sage X3, Adonix X3, was purchased by Sage in 2005.

sage x3 pharmaceuticals

Earlier in Mr. Greene’s career, he held multiple leadership positions at AstraZeneca , and was a partner of Andersen Consulting, where he was responsible for the pharmaceutical/biotechnology marketing and sales practice. He is a member of the board of the Pharmaceutical Research and Manufacturers of America . Under her leadership, our regulatory team fosters innovation and efficiency in developing new treatments for CNS disorders, while ensuring compliance with laws and regulations via transparent and data-driven decision-making. Amy joined us in 2014 and was responsible for building our successful Regulatory and Quality organizations.

Supercharge your business with Sage X3 features

Jim received a Bachelor of Arts degree in government from Harvard College and a Master of Business Administration from Harvard Graduate School of Business Administration. Matt Lasmanis joined Sage as Chief Technology and Innovation Officer in November 2020. In this role, Matt leads Sage’s digital innovation, data, analytics, and enterprise-wide technology capabilities. Matt was previously at GlaxoSmithKline where he served as Vice President and CIO for GSK’s $10 billion U.S. affiliate and held global leadership roles of increasing responsibility in the areas of Oncology, Biopharmaceuticals, and Research & Development.

And Ph.D. degrees in Statistics from the University at Buffalo, NY and M.S. Degree in Applied Mathematics from the University of Toledo, OH. AJ is a fellow of the American Statistical Association and for over 8 years served on the editorial boards ofStatistics in MedicineandJournal of Biopharmaceutical Statistics. Government Affairs for MedImmune, a wholly owned subsidiary of AstraZeneca. Vanessa began her career working as a staff member in the United States Congress, where she served as a senior health policy advisor.

sage x3 pharmaceuticals

He held numerous leadership roles in multiple therapeutic categories and global markets at Pfizer, Wyeth and Johnson & Johnson. Mr. Germano was also Co-Chair of the Portfolio Strategy and Investment Committee focused on maximizing the return on research and development investment across the Pfizer portfolio. In addition, while in this role he directed the integration of Wyeth and Pfizer Specialty Care and Vaccines Businesses and developed top talent within the organization focusing on the leadership team. Barry E. Greene joined the Sage Board of Directors in October 2020 and brings over 30 year of experience to this position. He most recently served as President of Alnylam Pharmaceuticals, Inc., since 2007 and he previously held the position of Chief Operating Officer when he first joined the company in 2003. Prior to joining Millennium in 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com, a healthcare consulting company.


Prior to Sunovion, Amy held leadership roles in regulatory affairs at various biotech and device companies and was an integral part of the quality teams. Michael currently serves as Chief Executive Officer of Cerecor, Inc., formerly Aevi Genomic Medicine, Inc., a position he has held since February 2020, when Cerecor acquired Aevi. Prior to joining Cerecor, Mr. Cola served as President and Chief Executive Officer of Aevi since 2013.

sage x3 pharmaceuticals

He most recently served as Director and Head of Neuroscience for the CNS and pain innovative medicine unit of AstraZeneca Pharmaceuticals in Sodertalje, Sweden, where he was responsible for leading preclinical research in neurology and pain control. Previously, Jim was Director and Head of the Neuroscience Department at AstraZeneca Pharmaceuticals in Wilmington, Del., where he led preclinical research in psychiatry and cognition. He has experience with discovery, translational science and early development in several areas of neuroscience research, including psychiatry, neurology, cognition, epilepsy and analgesia.

Potency Management for Pharmaceuticals in Sage X3

Earlier in his career, Jim was a Vice President in charge of the East Coast Life Sciences Practice at Robertson Stephens & Company. He also worked in healthcare investment banking at Morgan Stanley & Company and spent a year teaching secondary school at the Royal Shrewsbury School in the U.K., as the Harvard College Fellow. Jim served on the Board of Directors of GPC Biotech AG from June 2004 to June 2009 and was a national director of the Association of Bioscience Financial Officers. He also serves as a Trustee for St. Francis House, Boston’s largest day shelter for the homeless. He has previously served as a trustee and Treasurer for the Roxbury Latin School and St Paul’s School.

Senior Vice President, Discovery Research

Before GSK, Matt led the digital platforms team at HarperCollins Publishers. Erin built and fosters the high-performing culture that has made Sage a success, nurturing it as the Company has grown from a small startup to a major player in biotech and CNS. She joined Sage in 2014 with more than 20 years of experience in developing human resources strategies and programs. Previously, Erin served as Executive Director, Human Resources, Global Commercialization at Bristol-Myers Squibb . In 2009, Erin relocated to Paris where she was the HR Director for European Markets at BMS, serving as the strategic business partner responsible for all aspects of HR across multiple European commercial, R&D and corporate functions.

Advancing a leading brain health portfolio

It briefly gained a longer name between 2017 and 2019, Sage Business Cloud Enterprise Management, as part of Sage’s Sage Business Cloud offering, before returning to its previous Sage X3 name. He completed a residency in psychiatry at Harvard and then served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School. In biomedical engineering at the University of Virginia, and her B.S. In 2014, Amy was named as one of the Boston Business Journal/Mass High Tech 2014 Women to Watch. Prior to his tenure at Rush, Dr. Pollack was Director of the Center for Anxiety and Traumatic Stress Disorders and Professor of Psychiatry at Massachusetts General Hospital and Harvard Medical School. He established a groundbreaking research career supported by over 25 years of continuous federal funding, focused on a multidisciplinary neuroscientific approach to anxiety and mood disorders, PTSD and substance abuse.

Dr. Gault brings more than 15 years of pharmaceutical industry experience advancing programs at early and late stages of development in rare and common diseases. She has led multidisciplinary teams focusing in neuropsychiatry, neuroinflammation and neurodegeneration and has extensive knowledge of clinical trial design and conduct, and the regulatory landscape in these areas. Prior to that, she held positions as Vice President, Neurology Clinic Development at Vertex Pharmaceuticals and Group Project Leader at AbbVie.

The benefit that we received immediately was the ability to open a second manufacturing facility.

Barry E. Greene joined Sage as CEO in December of 2020, bringing more than 30 years of biopharmaceutical industry experience to this position. Prior to Sage, he served as president of Alnylam Pharmaceuticals, Inc. since 2007, and he previously held the position of chief operating officer when he first joined the company in 2003. Food and Drug Administration approval and launch of VELCADE® in mid-2003. Prior to joining Millennium in 2001, Mr. Greene served as executive vice president and chief business officer for Mediconsult.com, a healthcare consulting company.

With over 15 years of diverse industry experience, Mike has been critically involved, as both scientific and program lead, in over 10 programs that have made the transition from preclinical to clinical development. He has been a member of the Group of Fifty and served on the Board of the Biotechnology Innovation Organization, where he was a member of the Executive Committee and Chaired the International Committee. He continues to serve on the Advisory Board of the Healthcare Businesswomen’s Association and as a Trustee of the Albany College of Pharmacy where he received his Bachelor of Science degree in Pharmacy. Geno was formerly a Director of Zoetis Inc., and is currently a director of Bioverativ. He most recently served as Vice President, Global Head of Commercial Excellence at Alexion, where he led integrated global launch planning and readiness.